These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 26496778)

  • 1. Correlation of Bone Mineral Density Scores and Proton Pump Inhibitors Use in the Elderly.
    Amoako AO; Jafilan L; Nasiri P; Pujalte GG
    Curr Rheumatol Rev; 2016; 12(2):162-6. PubMed ID: 26496778
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correlation of Bone Mineral Density Scores and Proton Pump Inhibitors Use in the Elderly.
    Amoako AO; Jafilan L; Nasiri P; Pujalte GG
    Curr Rheumatol Rev; 2016 Mar; ():. PubMed ID: 27030255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proton pump inhibitors use and change in bone mineral density.
    Arj A; Razavi Zade M; Yavari M; Akbari H; Zamani B; Asemi Z
    Int J Rheum Dis; 2016 Sep; 19(9):864-8. PubMed ID: 27242025
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss.
    Targownik LE; Lix LM; Leung S; Leslie WD
    Gastroenterology; 2010 Mar; 138(3):896-904. PubMed ID: 19931262
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Esomeprazole use is independently associated with significant reduction of BMD: 1-year prospective comparative safety study of four proton pump inhibitors.
    Bahtiri E; Islami H; Hoxha R; Qorraj-Bytyqi H; Rexhepi S; Hoti K; Thaçi K; Thaçi S; Karakulak Ç
    J Bone Miner Metab; 2016 Sep; 34(5):571-9. PubMed ID: 26209167
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The relationship between proton pump inhibitor use and longitudinal change in bone mineral density: a population-based study [corrected] from the Canadian Multicentre Osteoporosis Study (CaMos).
    Targownik LE; Leslie WD; Davison KS; Goltzman D; Jamal SA; Kreiger N; Josse RG; Kaiser SM; Kovacs CS; Prior JC; Zhou W;
    Am J Gastroenterol; 2012 Sep; 107(9):1361-9. PubMed ID: 22777336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Associations between Proton Pump Inhibitor and Histamine-2 Receptor Antagonist and Bone Mineral Density among Kidney Transplant Recipients.
    Lyu B; Hansen KE; Jorgenson MR; Astor BC
    Am J Nephrol; 2020; 51(6):433-441. PubMed ID: 32485707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of proton pump inhibitors is associated with lower trabecular bone density in older individuals.
    Maggio M; Lauretani F; Ceda GP; De Vita F; Bondi G; Corsonello A; Cattabiani C; Lattanzio F; Ruggiero C; Nouvenne A; Meschi T; Bandinelli S; Ferrucci L
    Bone; 2013 Dec; 57(2):437-42. PubMed ID: 24076021
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proton pump inhibitor omeprazole use is associated with low bone mineral density in maintenance haemodialysis patients.
    Kirkpantur A; Altun B; Arici M; Turgan C
    Int J Clin Pract; 2009 Feb; 63(2):261-8. PubMed ID: 19196364
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [The risks of long-term proton pump inhibitors use].
    Jiang X; Zhang Q; Zhang Z; Liu Y
    Zhonghua Yi Xue Za Zhi; 2014 Jan; 94(4):284-8. PubMed ID: 24731496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone mineral density changes among women initiating proton pump inhibitors or H2 receptor antagonists: a SWAN cohort study.
    Solomon DH; Diem SJ; Ruppert K; Lian YJ; Liu CC; Wohlfart A; Greendale GA; Finkelstein JS
    J Bone Miner Res; 2015 Feb; 30(2):232-9. PubMed ID: 25156141
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship between long-term proton pump inhibitor therapy and skeletal frailty.
    Lau AN; Tomizza M; Wong-Pack M; Papaioannou A; Adachi JD
    Endocrine; 2015 Aug; 49(3):606-10. PubMed ID: 25948072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The prevalence of significant left-right differences in hip bone mineral density.
    Hamdy R; Kiebzak GM; Seier E; Watts NB
    Osteoporos Int; 2006 Dec; 17(12):1772-80. PubMed ID: 17019523
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proton Pump Inhibitor Use and Bone Health in Patients With Rheumatic Diseases: A Cross-Sectional Study.
    Palmowski A; Schmajuk G; Yazdany J; Katz P; Li J; Stovall R; Kersey E; Nielsen SM; Christensen R; Bliddal H; Boyadzhieva Z; Schneider U; Alexander T; Muche B; Hermann S; Wiebe E; Buttgereit F
    Mayo Clin Proc; 2024 Jul; 99(7):1046-1057. PubMed ID: 38752948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prescribing of anti-osteoporotic therapies following the use of proton pump inhibitors in general practice.
    McGowan B; Bennett K; Barry M
    Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):763-9. PubMed ID: 20582909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bone density in proton pump inhibitors users: a prospective study.
    Ozdil K; Kahraman R; Sahin A; Calhan T; Gozden EH; Akyuz U; Erer B; Sokmen MH
    Rheumatol Int; 2013 Sep; 33(9):2255-60. PubMed ID: 23455632
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Association Between Prolonged Proton Pump Inhibitors Use and Bone Mineral Density.
    Fattahi MR; Niknam R; Shams M; Anushiravani A; Taghavi SA; Omrani GR; Mahmoudi L
    Risk Manag Healthc Policy; 2019; 12():349-355. PubMed ID: 31853206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fracture risk and bone mineral density reduction associated with proton pump inhibitors.
    Lau YT; Ahmed NN
    Pharmacotherapy; 2012 Jan; 32(1):67-79. PubMed ID: 22392829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PPI-Induced Changes in Plasma Metabolite Levels Influence Total Hip Bone Mineral Density in a UK Cohort.
    Zhang X; Adebayo AS; Wang D; Raza Y; Tomlinson M; Dooley H; Bowyer RCE; Small KS; Steves CJ; Spector TD; Duncan EL; Visconti A; Falchi M
    J Bone Miner Res; 2023 Feb; 38(2):326-334. PubMed ID: 36458982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bone microstructure in proton pump inhibitor users.
    Kondapalli A; Agarwal S; Germosen C; Bucovsky M; Colon I; Kil N; Walker M
    Bone; 2023 Mar; 168():116668. PubMed ID: 36621542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.